Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies. Part 2. The Women's Health Initiative: Estrogen plus progestogen

Journal of Family Planning and Reproductive Health Care

Volumn 37, Issue 3, 2011, Pages 165-172

  Shapiro, Samuel ^a   Farmer, Richard D T ^b   Mueck, Alfred O ^c   Seaman, Helen ^d   Stevenson, John C ^e  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d Royal Brompton Hospital ^*

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN DERIVATIVE; ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; MEDROXYPROGESTERONE ACETATE; PLACEBO; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST EXAMINATION; BREAST TENDERNESS; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER INVASION; CANCER RISK; CARCINOMA IN SITU; CAUSAL ATTRIBUTION; CONFOUNDING VARIABLE; EARLY TERMINATION OF CLINICAL TRIAL; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; INTERNAL CONSISTENCY; MAMMOGRAPHY; MENOPAUSE; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STATISTICAL SIGNIFICANCE; SYSTEMATIC ERROR; VAGINA BLEEDING;

AGED; BREAST NEOPLASMS; CAUSALITY; DATA INTERPRETATION, STATISTICAL; ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MIDDLE AGED; RESEARCH DESIGN;

EID: 79961092761     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1136/jfprhc-2011-0090     Document Type: Article

References (28)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047-1059.
2. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
3. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
4. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
5. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670-1674.
6. Shapiro S, Farmer RDT, Seaman H, et al. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies. Part 1. The Collaborative Reanalysis. J Fam Plann Reprod Health Care 2011;37: 103-109.
7. Hill AB. The environment and disease: association or causation? Proc Royal Soc Med 1965;58:295-300.
8. Susser M. Causal Thinking in the Health Sciences. New York, NY: Oxford University Press, 1979.
9. Department of Health, Education and Welfare. Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service. Washington, DC: U.S. Government Printing Office, 1964.
10. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-3253. (Pubitemid 37430077)
11. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006;55:103-115. (Pubitemid 44307491)
12. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036-1045. (Pubitemid 351347060)
13. Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010;304:1684-1692.
14. Prentice RL, Chlebowski RT, Stefanick ML, et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 2008;167:1207-1216.
15. Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009;360:573-587.
16. Prentice RL, Manson JE, Langer RD, et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. AmJ Epidemiol 2009;170:12-23.
17. Shapiro S, Farmer RDT, Mueck AO, et al. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies. Part 3: unopposed estrogen. J Fam Plann ReprodHealth Care 2011;37:(in press).
18. Hays J, Hunt JR, Hubbell FA, et al. The Women's Health Initiative recruitment methods and results. Ann Epidemiol 2003;13:S18-S77. (Pubitemid 37324176)
19. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. JAMA 1996;275:370-375.
20. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-1886. (Pubitemid 20026073)
21. Welch HG, Black WC. Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med 1997;127:1023-1028.
22. Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 1999;130:262-269. (Pubitemid 29091853)
23. Rosenberg RD, Hunt WC, Williamson MR, et al. Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico. Radiology 1998;209:511-518. (Pubitemid 28503121)
24. Prentice RL, Chlebowski RT, Rossouw JE, et al. Four authors reply [Letter to the Editor]. Am J Epidemiol 2008;168:1213-1214.
25. Shapiro S. Bias in the evaluation of low-magnitude associations: an empirical perspective. Am J Epidemiol 2000;151:939-945. (Pubitemid 30463571)
26. Dietel M, Lewis MA, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod 2005;20:2052-2060. (Pubitemid 41418488)
27. Mueck AO, Seeger H, Shapiro S. Risk of breast cancer during hormone replacement therapy: mechanisms. Horm Biol Clin Invest 2010;3:329-339.
28. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95:s1-s66.